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Abstract 
 O-GlcNAc transferase (OGT)-mediated modification of protein Ser/Thr residues 
with O-GlcNAc influences protein activity, similar to the effects of phosphorylation.  
The anti-apoptotic Akt1 is both activated by phosphorylation and modified with O-
GlcNAc.  However, the nature and significance of the Akt1 O-GlcNAc modification is 
unknown.  The relationship of O-GlcNAc modification and phosphorylation at Akt1 
Ser473 was examined with respect to apoptosis of murine β-pancreatic cells.  
Glucosamine treatment induced apoptosis, which correlated with enhanced O-GlcNAc 
modification of Akt1 and concomitant reduction in Ser473 phosphorylation.  
Pharmacological inhibition of OGT or O-GlcNAcase revealed an inverse correlation 
between O-GlcNAc modification and Ser473 phosphorylation of Akt1.  MALDI-
TOF/TOF mass spectrometry analysis of Akt1 immunoprecipitates from glucosamine-
treated cells, but not untreated controls, showed a peptide containing S473/T479 that 
was presumably modified with O-GlcNAc.  Furthermore, in vitro O-GlcNAc-
modification analysis of wildtype and mutant Akt1 revealed that S473 was targeted by 
recombinant OGT.  A S473A Akt1 mutant demonstrated reduced basal and 
glucosamine-induced Akt1 O-GlcNAc modification compared with wildtype Akt1.  
Furthermore, wildtype Akt1, but not the S473A mutant, appeared to be associated with 
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OGT following glucosamine treatment.  Together, these observations suggest that 
Akt1 Ser473 may undergo both phosphorylation and O-GlcNAc modification, and the 
balance between these may regulate murine β-pancreatic cell fate. 
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 In contrast to N-linked glycosylation of membrane or secreted proteins, attachment 
of the monosaccharide of O-linked N-acetylglucosamine (O-GlcNAc) to Ser and/or Thr 
residues occurs mainly on nuclear and cytosolic proteins [1, 2].  The O-GlcNAc 
modification is dynamically catalyzed by O-GlcNAc transferase (OGT) [3] and 
removal of O-GlcNAc is achieved by O-GlcNAc-selective N-acetyl-β-D-
glucosaminidase (O-GlcNAcase) [4].  O-GlcNAc modification of Ser/Thr residue(s) 
on a specific protein can modulate the activity of that molecule to the extent of 
ultimately regulating cell function or behavior [2, 4]. 
 Many studies have indicated that activation of hexosamine biosynthesis pathway 
(HBP), which serves as a nutrient sensor, can lead to abnormalities in protein O-
GlcNAc modification that may be associated with insulin resistance and diabetic 
complications [5].  When physiological changes in extracellular glucose 
concentrations are detected by β-pancreatic cells that are uniquely enriched with OGT 
[6], glucose is converted to glucose-6-phosphate and then to fructose-6-phosphate [7].  
The rate-limiting conversion of fructose-6-phosphate to glucosamine-6-phosphate is 
mediated by L-glutamine:fructose-6-phosphate amidotransferase (GFAT) [8].  
Glucosamine-6-phosphate can subsequently be converted to UDP-N-acetylglucosamine 
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(UDP-GlcNAc), the requisite substrate for O-GlcNAc modification of many different 
proteins [9].  Therefore, an enhanced glucose flux through the HBP can increase O-
GlcNAc-modification of proteins in response to nutrient levels.  Intracellular 
accumulation of O-GlcNAc-modified proteins can also be achieved by inhibition of O-
GlcNAcase [4]. 
 Patients with type II diabetes are characterized by reduced secretion of insulin by β-
pancreatic cells in response to hyperglycemia combined with impaired ability of 
skeletal muscle, fat and liver cells to respond to insulin [10].  The failure of β-cells to 
compensate for the insulin demand results from reduced β-cell mass through their 
necrosis and apoptosis [11].  Thus, a loss in pancreatic β-cell mass may intensify the 
functional defects, and cause further impairment of the aberrant insulin secretion 
observed in inefficiently controlled diabetes [12].  O-GlcNAc modification of certain 
proteins is known to be associated with β-cell apoptosis in hyperglycemic conditions 
[11]. 
 The anti-apoptotic protein Akt1 is activated by phosphorylation [13]; specifically, 
phosphorylation at Thr308 and Ser473 is required for full Akt1 activity [14].  Akt1 in 
turn phosphorylates diverse downstream molecules including caspase 3, Bad, forkhead 
transcription factor (FOXO family), and GSK3β, inhibiting their pro-apoptotic 
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activities and promoting cell survival [14].  Interestingly, the phosphorylation level of 
Ser473 is modulated by hyperglycemic conditions [12], and Akt1 may also be modified 
with O-GlcNAc [15].  However, it is currently not clear which Ser/Thr residue(s) of 
Akt1 are O-GlcNAc-modified and how the O-GlcNAc modification is related to its 
phosphorylation.  Results of this study indicate that Akt1 Ser473 may be modified 
with O-GlcNAc, and that O-GlcNAc modification and phosphorylation of Ser473 are 
reciprocally regulated by hyperglycemic treatment in murine β-pancreatic cells. 
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Materials and Methods 
Cell cultures: βTC-6 (ATCC), an insulinoma cell line isolated from mouse pancreas, 
was grown in RPMI-1640 containing 10% FBS (WelGENE, Daegu, Korea) in 5% CO2 
at 37oC.  INS-1, an insulinoma cell line isolated from rat pancreas, was grown in 
RPMI-1640 culture medium containing 10% FBS, 1 mM sodium pyruvate, 10 mM 
HEPES and 50 μM 2-mercaptoethanol in 5% CO2 at 37oC.  INS-1 cells that stably 
express human nucleocytoplasmic OGT (ncOGT) were prepared by transfection with 
mammalian ncOGT plasmid (Gene accession number DQ893623; cDNA cloned into 
pcDNA3 vector at BamHI/NotI restriction sites) and selection with G418 (500 μg/ml).  
βTC-6 and INS-1 cells were subcultured at a 1:4 ratio once a week and maintained 
between passages 18 and 35.  Culture media were changed every 48 h. 
Cell extract preparation and Western blots: βTC-6 or INS-1 cells were incubated in the 
normal culture media or serum-free media with containing glucosamine in 0.5 mM 
HEPES, pH 7.5 (Sigma) at the indicated concentrations for different time periods prior 
to lysis with a modified RIPA lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 50 mM 
NaF, 1 mM sodium pyrophosphate, 0.1% sodium deoxycholate, 1% NP-40 and protease 
inhibitors).  In certain experiments, INS-1 cells were treated with RPMI-1640 with 
11.1 (normal glucose, NG), 22.2, or 33.3 mM glucose and compensated with mannitol 
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for osmotic balance.  When required, pharmacological inhibitor against OGT 
[BADGP (Calbiochem) or Alloxan (Sigma)] or O-GlcNAcase (PUGNAc, Toronto 
Research Chemical Inc., Ontario, Canada) was directly added to serum-free culture 
media at the indicated concentrations 1 h before treatment with glucosamine in 0.5 mM 
HEPES (pH 7.5).  Protein concentration of lysates was quantitated by the BCA 
(Pierce) method, and normalized prior to analysis by standard Western blot procedures 
using antibodies against phospho-S473Akt, phospho-T308Akt, Akt, phospho-S9GSK3β, 
GSK3β, active caspase-3 (Cell Signaling), OGT (Sigma), and O-GlcNAc (RL2 clone 
from Affinity BioReagent or CTD110.6 clone from Convence). 
S473A and T479A Akt1 mutation: pCMV5-(HA)3-Akt1 wildtype (WT) was point-
mutated at Ser473 or Thr479 using the Quick-change site-directed mutagenesis system 
(Stratagene).  In each case, mutation to Ala was confirmed by direct sequence analysis. 
Immunoprecipitation: INS-1 cells were treated with glucosamine in 0.5 mM HEPES 
(pH 7.5) at different concentrations for 14 h in the absence of serum, then lysed with 
modified RIPA buffer.  Lysate containing 500 μg protein was mixed with anti-O-
GlcNAc (RL-2 clone) or anti-Akt antibody (0.5 μg/condition) and rotated for 2 h at 4oC.  
Protein A/G sepharose beads (30 μl of 50% slurry, Upstate) were added to the mixture 
before an additional 2 h rotation at 4oC.  The immunoprecipitates were collected, 
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washed, and eluted prior to standard Western blot analysis [16]. 
DNA content analysis: Subconfluent INS-1 cells in serum-free media were treated 
without or with glucosamine in 0.5 mM HEPES (pH 7.5) at different concentrations for 
22 h before propidium iodide (PI) staining for 30 min and FACS analysis as described 
previously [17]. 
Expression and elution of recombinant fusion proteins: Human ncOGT was cloned into 
pGEX-6p-2 vector (GE healthcare) at BamHI/NotI cloning sites.  Mouse Akt1 WT, 
S473A mutant, or T479A mutant were cloned into pET-28a-c(+) vector (Novagen) at 
BamHI/EcoRI cloning sites.  The sequence of each construct was confirmed by direct 
sequence analysis.  Recombinant proteins were induced in BL21 E.coli strain by 0.3 
mM IPTG for 3 h, prior to extraction via sonications.  Bacterial extracts were 
incubated with glutathione-sepharose or Ni2+-conjugated NTA (nitroloacetic acid) beads 
for 1 h and recombinant proteins were eluted from beads with GST fusion protein 
elution buffer (50 mM Tris-HCl, pH 8.2, 2 mM MgCl2, 0.2 mM Na2S2O5, 10% 
Glycerol, 20% Sucrose, 2 mM DTT, 1 mM Na2VO4, and protease inhibitors) or with 
(His)6 fusion protein elution buffer (8 M Urea, 50 mM Tris-HCl, pH 8.0, and 10 mM 
DTT) from beads.  
In vitro O-GlcNAc modification assay: Recombinant (His)6-Akt1 WT, S473A, or 
 10
T479A protein bound to Ni2+-NTA beads was washed with ice-cold PBS and incubated 
with 2 μg recombinant GST-ncOGT protein and 1 μM UDP-GlcNAc in OGT activity 
assay buffer (50 mM Tris-HCl, pH 7.5, 12.5 mM MgCl2, and 1 mM β-mercaptoethanol) 
for 30 min at 22oC.  In specific cases, ncOGT was inhibited by 1 mM BADGP (benzyl-
2-acetamido-2-deoxy-alpha-d-galactopyranoside).  After incubation, the reaction 
mixture was washed three times with ice-cold PBS, then 2x SDS-PAGE sample buffer 
was added to the mixtures prior to boiling for 5 min.  Standard Western blots using 
anti-O-GlcNAc (CTD 110.6 clone) (Convence) antibody were performed. 
2D-PAGE: Akt1 immunoprecipitates were prepared from control or INS-1 cells treated 
with 7.5 mM glucosamine in the absence of serum and solubilized in rehydration buffer 
(9 M urea, 2% CHAPS, 60 mM DTT, 0.5% pharmalyte, pH 4-7, 0.002% bromophenol 
blue).  Protein samples were loaded onto IPG strips and rehydrated overnight, then 
IEF gels were run as described previously [18].  Briefly, pre-cast immobilized pH 
gradient strips (24 cm, pH 4-7, linear, Amersham Biosciences, Uppsala, Sweden) for 
isoelectric focusing (IEF) were equilibrated for 15 min in a reducing solution (50 mM 
Tris-HCl, pH 8.8, 6 M urea, 30%(v/v) glycerol, 2% (w/v) SDS, 1% (w/v) DTT), and 
then for a further 15 min in an alkylating solution, which was identical to the reducing 
solution except that 2.5% (w/v) iodoacetamide was substituted for DTT.  Gel 
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electrophoresis was performed by standard 8% SDS-PAGE, and proteins were 
visualized by silver staining or immunoblotted with anti-O-GlcNAc (CTD 110.6 clone). 
MALDI-TOF/TOF: Spots on silver-stained gels corresponding to Akt1 were excised, 
destained by reduction using 30 mM potassium ferricyanide/100 mM sodium 
thiosulfate, and washed with distilled water for MALDI-TOF/TOF analysis as 
described previously [19].  Briefly, gel pieces were incubated with 0.2 M NH4HCO3 
for 20 min, dehydrated, shrunk twice with 100% acetonitrile, and dried by vacuum 
centrifugation.  For “in-gel” trypsin digestion of Akt1 immunoprecipitates, gel pieces 
were rehydrated in digestion buffer containing 0.05 M NH4HCO3 and 10 ng/μl of 
modified porcine trypsin (Promega) at 4oC for 45 min.  Excess supernatant was then 
removed, and the gel pieces were covered with 0.05 M NH4HCO3 buffer.  Digestion 
was performed overnight at 37oC, then tryptic peptides were extracted from the gel 
particles, desalted using a GELoader tip, and packed with POROS 20R2 resin (Applied 
Biosystems Inc.).  Peptide binding and washing were performed in 0.1% 
trifluoroacetic acid (TFA) in water.  To produce the MALDI sample matrix, α-cyano-
4-hydroxy cinnamic acid was dissolved at a concentration of 5 g/l in a solution 
containing 70% acetonitrile and 0.1% TFA.  Elution was performed with 1 μl of 
sample matrix and the eluted peptides were directly spotted on the target plate.  
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Protein identification was carried out by peptide mass fingerprinting (PMF) using matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer 
(Voyager DE-PRO MALDITOF mass spectrometer) (Biosystems Inc.).  Mass spectra 
were registered in reflectron positive ion mode and mass accuracy was set at 50 ppm.  
Database searches for PMF were performed using the MASCOT search program 
developed by Matrix Science Ltd. (access is available on 
http://www.matrix.science.com), with the NCBI database (http://www. 
ncbi.nlm.nih.gov/entrez), and using the ExPASy Molecular Biology Server at the 
SWISSPROT database (http://www.expasy.org). 
Statistical analysis: The relative levels of pS473Akt1 and O-GlcNAc-modified Akt1 
were calculated after normalization against Akt1 band intensities measured by a 
densitometry and presented as mean ± standard deviation.  Mean values were 
compared using Student’s t-test; p values < 0.05 were considered significant. 
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Results 
Glucosamine treatment induced apoptosis of murine β-pancreatic cells. 
 To confirm that glucosamine-mediated hyperglycemic conditions induced cell death, 
rat INS-1 β-pancreatic cells were treated with glucosamine dissolved in 0.5 mM 
HEPES (pH 7.5) at different concentrations.  Cells were treated with glucosamine 
under osmotic control by mannitol in the absence of serum, and viable cells were 
counted after trypan blue staining.  Glucosamine treatment of INS-1 cells induced cell 
death (Fig. 1A), activated caspase 3 (Fig. 1B) and significantly increased the sub-G1 
population in a dose-dependent manner (Fig.1C).  Treatment with 7.5 mM 
glucosamine for less than 6 h showed a less significant apoptotic rate of ~ 9.0% (data 
not shown), therefore cells were generally treated for 14 h in the following experiments.  
Treatment with glucosamine also induced cell death in mouse βTC-6 pancreatic cells 
(Fig. 1D).  These observations confirm that glucosamine treatment of murine β-
pancreatic cells caused caspase-dependent apoptosis. 
Hyperglycemic conditions increased O-GlcNAc modification and concomitantly 
decreased Ser473 phosphorylation of Akt1. 
 When murine β-pancreatic cells were treated with glucosamine (7.5 mM GlcN), the 
overall O-GlcNAc modification level of proteins increased with a particularly obvious 
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modification of an approximately 60 kD protein that may correspond to Akt1 protein 
involved in cell survival (Fig. 2A).  It is thus likely that O-GlcNAc modification of 
certain molecules, such as Akt1, was increased in glucosamine-mediated hyperglycemic 
conditions to regulate cell viability [10].  We next tested the level of O-GlcNAc-
modified Akt1 in murine β-pancreatic cells without or with glucosamine treatment by 
immunoblotting using anti-Akt1 antibody for O-GlcNAc immunoprecipitates or anti-O-
GlcNAc antibody for Akt1 immunoprecipitates.  The O-GlcNAc modification level of 
Akt1 increased in a glucosamine dose-dependent manner, whereas Akt1 Ser473 
phosphorylation (pS473Akt1) was concomitantly decreased (Fig. 2B).  Consistent with 
these findings, treatment with higher concentrations of glucose also increased O-
GlcNAc modification of Akt1 and decreased pS473Akt1 (Fig. 2C).  Furthermore, 
phosphorylation of GSK3β, a substrate of Akt1, was reduced following glucosamine 
treatment, indicating that glucosamine treatment decreased Akt1 activity (Fig. 2B).  
These observations indicate that Akt1 Ser473 phosphorylation, and thus activity, might 
be mutually exclusive with O-GlcNAc modification, although it is not clear whether the 
modified residues are the same. 
OGT or O-GlcNAcase inhibitor reciprocally regulated Akt1 O-GlcNAc 
modification and pS473Akt1. 
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 To further confirm the reciprocal relationship between O-GlcNAc modification and 
phosphorylation of Akt1, pharmacological inhibitors against OGT (BADGP or alloxan) 
or O-GlcNAcase (PUGNAc) were added to the culture media before glucosamine 
treatment.  When INS-1 cells were treated with either BADGP or alloxan in the 
absence or presence of 7.5 mM glucosamine, the basal and glucosamine-mediated Akt1 
O-GlcNAc modifications were decreased, whereas pS473Akt1 levels were increased 
(Fig. 3A and B).  On the other hand, when removal of O-GlcNAc was blocked by 
PUGNAc treatment, the basal pS473Akt1 level was slightly reduced, whereas 
glucosamine-mediated pS473Akt1 levels were not observed regardless of whether 
PUGNAc was treated or not (Fig. 3C).  Interestingly, pT308Akt1 levels were not 
significantly changed by PUGNAc treatment, although they were slightly reduced by 
treatment with 7.5 mM GlcN (Fig. 3C). 
The Akt1 Ser473 residue appeared to be modified with O-GlcNAc following 
glucosamine treatment. 
 It is reasonable to predict that O-GlcNAc modification and phosphorylation of Akt1 
both occur at the Ser473 residue in a reciprocal manner.  Based on analysis by the 
YinOYang 1.2 program (http://www.cbs.dtu.dk/services/YinOYang/) [20], we found 
that Akt1 may be modified with O-GlcNAc at Ser122, Thr430, Ser473, and/or Thr479 
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residues, with the highest potential value of O-GlcNAc modification at Ser473 (Table 
1).  Thus, to map the O-GlcNAc modification site(s) of Akt1, we performed MALDI-
TOF/TOF analysis with tryptic-digested peptides of Akt1 immunoprecipitates.  Whole 
cell extracts from INS-1 cells without or with 7.5 mM glucosamine treatment were 
immunoprecipitated with anti-Akt1 antibody, and the immunoprecipitates were 
separated by 2D electrophoresis prior to immunoblotting with anti-O-GlcNAc antibody 
(CTD 110.6 clone) (Fig. 4A).  Akt1 was excised from silver-stained 2D 
electrophoresis gels and digested with trypsin prior to MALDI-TOF/TOF analysis.  
The unmodified 466-480 peptide of Akt1 at [M+H]+ m/z 1652.72 was observed among 
the tryptic-digested peptides prepared from control and glucosamine-treated cells (Fig. 
4B).  When the Ser or Thr residue is modified with O-GlcNAc the mass would be 
predicted to increase by ~ 203 dalton, therefore we screened for tryptic-digested 
peptide(s) of Akt1 with an increased mass of ~ 203 dalton.  Interestingly, the presumed 
O-GlcNAc-modified 466-480 peptide of Akt1 was observed at [M+H]+ m/z 1854.22 
among the tryptic-digested peptides prepared from the glucosamine-treated cells, but 
not from control cells (Fig. 4B, bottom).  This observation indicates that glucosamine 
treatment of INS-1 cells causes O-GlcNAc modification of Akt1, presumably at either 
Ser473 or Thr479. 
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Akt1 WT and T479A mutant, but not S473A mutant, were O-GlcNAc-modified by 
recombinant OGT. 
 Since Thr479 of Akt1 showed a tendency for O-GlcNAc modification in the 
YinOYang analysis (Table 1) and the O-GlcNAcylated peptide of Akt1 contained 
Thr479, we examined whether Ser473 and/or Thr479 were targeted by OGT using an in 
vitro O-GlcNAc modification assay.  Bacterial extracts of GST-ncOGT were incubated 
with recombinant (His)6-Akt1 WT, S473A mutant, or T479A mutant bound to Ni2+-
NTA beads as the substrate.  Compared with a mock control substrate of plain (His)6-
vector alone without Akt1 insert, O-GlcNAc modification of WT Akt1 was increased 
(Fig. 5A, lanes 1 and 2), whereas the Akt1 S473A mutant was not modified (Fig. 5A, 
lane 3).  Interestingly, the T479A mutant was robustly modified with O-GlcNAc, even 
more than WT Akt1 (Fig. 5A), indicating that Thr479 was not an O-GlcNAc 
modification site, and further suggesting that the T479A mutation might have caused 
structural changes that increased access of ncOGT to other Ser/Thr residue(s) on Akt1, 
including Ser473.  The in vitro O-GlcNAc modification of (His)6-Akt1 by 
recombinant GST-ncOGT occurred in a dose-dependent manner (Fig. 5B), and was 
blocked by treatment with the OGT inhibitor BADGP (Fig. 5C), indicating that the O-
GlcNAc modification observed in the in vitro assay was indeed mediated by OGT 
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activity. 
Intracellular O-GlcNAc modification of the S473A Akt1 mutant was not observed 
following glucosamine treatment or ncOGT overexpression. 
 We next examined whether O-GlcNAc-modification of the S473A Akt1 mutant 
occurred in an in vivo cellular system.  INS-1 cells were transfected with a mock 
control vector, (HA)3-Akt1 WT, or S473A mutant 24 h before treatment with control 
vehicle or glucosamine (7.5.mM) for 14 h.  Cell extracts were immunoblotted or 
immunoprecipitated with anti-O-GlcNAc antibody prior to Akt1 immunoblot analysis.  
In the absence of glucosamine, exogenous expression of Akt1 WT, but not S473A 
mutant, increased levels of pS473Akt1 (Fig. 6A, lanes 1 to 3).  However, pS473Akt1 
was not detected following glucosamine treatment, regardless of whether Akt1 WT or 
S473A mutant was expressed (Fig. 6A, lanes 4 to 6).  O-GlcNAc modification of Akt1 
occurred when the cells overexpressed Akt1 WT, but not S473A mutant protein, and 
was further increased when the cells were treated with glucosamine, compared with the 
untreated control (Fig. 6A, bottom).  Cell viability assays showed that viability was 
approximately 10% lower in cells transfected with the S473A Akt1 mutant than in cells 
transfected with WT Akt1 following treatment with control vehicle (5.7 ± 0.2 x 105 
versus 6.3 ± 0.3 x 105 cells, respectively) or GlcN (7.5 mM for 14 h) condition (3.3 ± 
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0.4 x 105 and 3.6 ± 0.4 x 105 cells, respectively) (data not shown).  This reduced 
viability of S473A Akt1-transfected cells, compared with WT transfected cells, was 
observed with a transfection efficiency of around 30-40%.  Furthermore, glucosamine 
treatment of cells transfected with WT or S473A Akt1 mutant resulted in a similar 
decrease in viability of 42-43%, indicating that O-GlcNAc-modified Akt1 (in the WT 
Akt1-transfected condition) or non-phosphorylated Akt1 (in the S473A Akt1-
transfected condition) have a similar effect on cell viability. 
 We further examined whether exogenous overexpression of ncOGT would regulate 
Akt1 O-GlcNAc modification and pS473Akt1 even in the absence of glucosamine 
treatment (Fig. 6B).  Cells that stably overexpress control vector or ncOGT were 
transiently transfected with either WT or S473A Akt1 and cell extracts were 
immunoblotted, or immunoprecipitated with anti-O-GlcNAc antibody before 
immunoblotting for Akt1.  When cells were transfected with Akt1 WT, ncOGT-
overexpressing cells showed a much higher level of Akt1 O-GlcNAc modification than 
control cells (Fig. 6C, lanes 1 and 3).  However, when the cells were transfected with 
S473A mutant Akt1, O-GlcNAc modifications were abolished in both control and 
ncOGT-overexpressing cells (Fig. 6C, lanes 2 and 4), further indicating that Ser473 is 
targeted by OGT.  Reciprocally, pS473Akt1 levels were partially reduced by 
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transfection with the S473A mutant, presumably due to incomplete transfection 
efficiency, and pS473Akt1 levels were lower in the ncOGT-overexpressing cells than in 
control cells (Fig. 6C).  Our observations that the Akt1 S473A mutation abolished O-
GlcNAc-modification, and that O-GlcNAc modification of Akt1 WT inversely 
correlated with pS473Akt1, suggest that O-GlcNAc modification at Akt1 Ser473 might 
compete with phosphorylation at Akt1 Ser473. 
OGT associated with Akt1 WT, but not S473A mutant, following glucosamine 
treatment. 
 We next examined the effect of hyperglycemic conditions on the localization of 
OGT and Akt1 via a coimmunoprecipitation approach.  Immunoprecipitates using 
anti-HA antibody from cells transfected with either WT Akt1 or S473A mutant Akt1 
tagged with (HA)3 were immunoblotted for OGT.  When treated with glucosamine, 
Akt1 WT co-immunoprecipitated OGT (presumably ncOGT of 116 kD), whereas 
S473A mutant did not (Fig. 7).  This observation suggests that modification of Akt1 
Ser473 with O-GlcNAc could be mediated by physical association between Akt1 and 
OGT, following a hyperglycemic treatment of INS-1 cells. 
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Discussion 
 Observations from this study indicated that Ser473 of Akt1 was modified with O-
GlcNAc when murine β-pancreatic cells were treated with glucosamine, a direct 
precursor of the downstream product of the hexosamine biosynthesis pathway (HBP).  
We found that a tryptic-digested peptide of Akt1 (amino acids 466 to 480 including 
Ser473 and Thr479) was modified with O-GlcNAc, consistent with theoretical 
predictions by the YinOYang 1.2 program that both Ser473 and Thr479 would be O-
GlcNAc-modified (http://www.cbs.dtu.dk/services/YinOYang/) (Table 1).  
Furthermore, the calculated potential for Ser473 to be O-GlcNAc-modified is higher 
than that for Thr479 (Table 1), and we observed that a T479A mutant of Akt1, but not a 
S473A mutant, maintained robust O-GlcNAc-modification in an in vitro O-GlcNAc 
modification assay.  Treatment with glucosamine or exogenous overexpression of 
mammalian ncOGT increased O-GlcNAc-modification of Akt1 WT, but not of S473A 
mutant, with a concomitant decrease in pS473Akt1.  Furthermore, Akt1 S473A mutant 
did not associate with OGT following treatment with glucosamine, whereas Akt1 WT 
did.  Together, these observations indicate that S473 Akt1 might be targeted by OGT in 
a glucosamine treatment-dependent manner.  The reciprocal relationship between 
increased O-GlcNAc-modification and decreased phosphorylation of Akt1 Ser473 upon 
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glucosamine treatment correlated with enhanced apoptotic death of murine β-pancreatic 
cells.  Since phosphorylation of Akt1 Ser473 is critical for its anti-apoptotic activity 
(14), we speculate that modification of Akt1 Ser473 plays an important role in 
determining the cell fate of murine β-pancreatic cells under conditions of extracellular 
hyperglycemia. 
 Since O-GlcNAc modification occurs at Ser/Thr residues, it is likely that O-GlcNAc 
modification and phosphorylation are reciprocally regulated under certain circumstances, 
leading to regulation of the protein’s activity and stability [21, 22].  Dynamic 
regulation of O-GlcNAc modification turnover in response to extracellular fluctuations 
in glucose levels may allow modulation of the signaling activities of certain intracellular 
proteins in β-pancreatic cells [4, 23, 24].  In particular, in diabetes mellitus, increased 
O-GlcNAc modification of many proteins under extracellular hyperglycemic conditions 
appears to be correlated with β-pancreatic cell death [11, 25]. 
 Glucosamine treatment of human islets of Langerhans and RIN rat β-pancreatic 
cells increases apoptosis due to serum-deprivation through impaired activation of the 
insulin receptor (IR)/IR substrate (IRS)/PI3-K/Akt survival pathway [10].  However, in 
this previous study, glucosamine treatment of β-pancreatic cells appeared to cause O-
GlcNAc modification of IR/IRS, upstream of PI3-K/Akt [10].  Although the O-
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GlcNAc modification residue was not determined, another report showed that Akt1 was 
shown to be O-GlcNAc-modified and phosphorylated in SH-SY5Y cells treated with 
insulin-like growth factor, and that PUGNAc-mediated accumulation of Akt1 O-
GlcNAc modification did not attenuate Akt1 phosphorylation with translocation of Akt1 
into the nucleus [15].  Therefore, Akt1 modification under hyperglycemic stimulations 
such as glucosamine treatment may be dependent on the signaling context and/or the 
cell type, which may have different expression levels of the proteins involved in the 
HBP pathway and O-GlcNAc modification turnover.  In this study, treatment with 
glucosamine increased O-GlcNAc modification of Akt1 Ser473, and concomitantly 
decreased phosphorylation of Akt1 Ser473 and its substrate, GSK3β, correlating with 
increased death of mouse βTC-6 and rat INS-1 β-pancreatic cells.  Our observations 
suggest that the balance between O-GlcNAc-modification and phosphorylation of Akt1 
Ser473 plays a role in the determination of apoptosis or survival of murine β-pancreatic 
cells, respectively, in response to hyperglycemic conditions induced by glucosamine 
treatment. 
 O-GlcNAc-modified proteins are typically phosphoproteins that play diverse roles 
in carbohydrate metabolism, signaling, gene regulation, and stress response [4].  This 
fact indicates that protein activity can depend on the nature of posttranslational 
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modifications that may ultimately regulate cell function or behavior, especially when 
the same Ser/Thr residue(s) on a specific protein may be modified with O-GlcNAc or 
O-phosphate.  Similar to our study for Akt1, estrogen receptor β (Ser16), c-Myc 
(Thr58), and endothelial nitric oxide synthase (eNOS, Ser1177) are also reciprocally O-
GlcNAc-modified or phosphorylated [26-28].  In the case of RNA polymerase II, 
multiple Ser/Thr residues in the COOH-terminal domain (CTD) are shown to be 
modified with O-GlcNAc or O-phosphate in a mutually exclusive manner, resulting in a 
reciprocal regulation of transcriptional elongation [29].  O-GlcNAc modification at 
Ser149 of p53 decreases the phosphorylation at Thr155 thereby stabilizing p53 by 
blocking ubiquitin-dependent proteolysis [21], indicating that these reciprocal 
modifications can also occur between adjacent residues.  For many proteins involved 
in signaling pathways, activity is determined by their phosphorylation status.  Since O-
GlcNAc modification at a particular Ser or Thr may sterically affect phosphorylation of 
the same or nearby residues, the activity of such proteins may also be regulated through 
O-GlcNAc modification.  Further investigation into the nature of O-GlcNAc 
modification may aid in the design and development of therapeutic reagents against 
diseases involving abnormal signaling activity such as type II diabetes and cancer. 
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Figure legends 
Fig. 1.  Glucosamine treatment caused death of murine β-pancreatic cells.  (A 
and D)  Rat or mouse β-pancreatic INS-1 (A) or βTC-6 (D) cells, respectively, seeded 
into 6 well culture plates.  One day after, serum was deprived and treatment of 
glucosamine (GlcN) in 0.5 mM HEPES (pH 7.5) was done at the indicated 
concentrations for 22 h.  Mannitol and glucose were parallelly used to compensate 
osmotic balance.  After incubation, viable cells were counted with a hemocytometer 
following trypan blue stain.  (B) INS-1 cells treated without or with 7.5 mM 
glucosamine (GlcN), as above, were harvested and immunoblotted for active caspase 3 
and α-tubulin.  (C) INS-1 cells were manipulated as in (A), before FACS analysis of 
PI-stained cells for DNA contents.  Data shown represent at least three independent 
experiments. 
 
Fig. 2.  Hyperglycemic conditions increased O-GlcNAc modification and 
concomitantly reduced Ser473 phosphorylation of Akt1.  (A)  INS-1 or βTC-6 
cells were treated without or with 7.5 mM glucosamine (GlcN) for the indicated periods 
in the absence of serum.  Whole cell lysates were prepared after incubation and used 
for standard Western blots to see O-GlcNAc-modified proteins.  Arrows indicate 
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molecular weights of protein markers.  (B) INS-1 (upper) or βTC-6 (lower) cells were 
treated with glucosamine at the indicated concentrations for 14 h in the absence of 
serum.  Both mannitol and glucose were included into the treatment for osmotic 
compensation, as in Fig. 1.  After incubation, cell lysates were prepared and used for 
standard Western blots for pS473Akt1, pS9GSK3β and Akt1 (lysates) or 
immunoprecipitated with anti-O-GlcNAc or anti-Akt antibody for immunoblots against 
Akt or O-GlcNAc (CTD 110.6 clone), respectively, to reveal O-GlcNAc modified Akt.  
(C) INS-1 cells were treated with glucose (11.1. mM normal glucose in RPMI-1640) at 
11.1, 22.2 or 33.3. mM for 3 days at osmotic balance with mannitol, before whole cell 
lysates preparation.  The lysates were immunoblotted or immunoprecipitated with anti-
Akt prior to immunoblots against Akt or O-GlcNAc (CTD 110.6 clone).  The relative 
pS473Akt1 and O-GlcNAc-modified Akt1 levels under diverse experimental conditions 
were calculated for graphic presentation (mean ± standard deviation) after 
normalization of them over Akt1 band intensities measured by a densitometry.  Data 
shown represent at least three independent experiments. 
 
Fig. 3.  OGT or O-GlcNAcase inhibitor regulated reciprocally Akt1 O-GlcNAc 
modification and pS473Akt1.  (A to C) OGT inhibitor, BADGP (A) or alloxan (B), or 
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O-GlcNAcase inhibitor, PUGNAc (C), was added to serum-deprived culture media.  
One hour later, cells were treated without or with 7.5 mM glucosamine (GlcN) for 14 h, 
prior to lysate harvests for standard Western blots (lysates in A, B and C) or 
immunoprecipitation (IP) with anti-O-GlcNAc antibody (RL2 clone) for Akt 
immunoblots.  Both mannitol and glucose were included for osmotic compensation 
(not depicted), as in Fig. 1.  The relative pS473Akt1 and/or O-GlcNAc-modified Akt1 
levels under diverse experimental conditions were calculated for graphic presentation 
(mean ± standard deviation) after normalization of them over Akt1 band intensities 
measured by a densitometry.  * indicates p values < 0.05 for significant differences.  
Data shown represent three different experiments. 
 
Fig. 4.  The Akt1 Ser473 residue modified with O-GlcNAc following glucosamine 
treatment.  (A) INS-1 cells were seeded and treated without or with 7.5 mM 
glucosamine (GlcN) in the absence of serum for 14 h, prior to cell harvests.  Both 
mannitol and glucose were included into the treatment for osmotic compensation (not 
depicted), as in Fig. 1.  Normalized lysates were immunoprecipitated with anti-Akt 
antibody.  Akt immunoprecipitates were processed for standard 2-D electrophoresis 
before immunoblots using anti-O-GlcNAc antibody (CTD 110.6 clone), as explained in 
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the Materials and Methods.  (B) The Akt spots on silver-stained gels, corresponding to 
circles of the anti-O-GlcNAc immunoblots as in (A), were cut and trypsinized.  The 
digests were processed for MALDI-TOF/TOF mass spectrometry to examine the 
existence of O-GlcNAc-modified Akt1 peptide including Ser473.  Note that 
hyperglycemic condition resulted in a peak corresponding to a peptide (amino acids 466 
to 480) including Ser473 with an O-GlcNAc modification, which causes an increase in 
mass (201.5 dalton) from 1652.72 to 1854.22 dalton. 
 
Fig. 5.  Akt1 WT, but not the S473A mutant, was O-GlcNAc-modified by 
recombinant ncOGT.  (A) Recombinant GST-human ncOGT was prepared from 
bacterial cultures, and recombinant mock, (His)6-Akt1 WT, S473A, or T479A proteins 
were purified and bound to Ni+-NTA beads.  Both recombinant GST-ncOGT and 
(His)6-Akt1 proteins were mixed with 1 μM UDP-GlcNAc, and the mixtures were 
incubated for 30 min at 22oC while shaking.  After incubation, the reaction mixture 
was diluted abundantly with the reaction buffer and spun down for washings.  SDS-
PAGE sample buffer (2 x) was added to the washed beads and boiled prior to recovery 
of proteins for standard Western blots using O-GlcNAc antibody (CTD 110.6 clone).  
(B) Different amount of recombinant mock, (His)6-Akt1 WT, or S473A proteins on Ni+-
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NTA beads were mixed with recombinant GST-human ncOGT for in vitro assay for O-
GlcNAc modification, as above.  (C) During the in vitro assay for mock, (His)6-Akt1 
WT or S473A mutant, as in (B), one set of reactions was untreated and the other set was 
treated with 3.3 mM BADGP, an OGT inhibitor.  In parallel, recombinant proteins on 
gels were stained with coomassie blue (A) or immunoblotted with either anti-GST (B) 
or anti-(His)6 antibody (C) for their equal loadings.  The relative O-GlcNAc-modified 
Akt1 levels under diverse experimental conditions were calculated for graphic 
presentation (mean ± standard deviation) based on band intensities measured by a 
densitometry.  * indicates p values < 0.05 for significant differences.  Data shown 
represent at least three isolated assays. 
 
Fig. 6.  No O-GlcNAc modification of S473A Akt1 mutant by glucosamine 
treatment or ncOGT overexpression.  (A) INS-1 cells were transiently transfected 
with mock, Akt1 WT or S473A mutant.  One day later, the cells were treated without 
(Control) or with 7.5 mM glucosamine (GlcN) in the absence of serum for 14 h.  After 
incubation, cell lysates were prepared and normalized for standard Western blots using 
anti-phospho-S473Akt1 or anti-HA antibody (lysate) or immunoprecipitated (IP) with 
anti-O-GlcNAc antibody (RL2 clone) prior to Akt1 immunoblots (bottom panel).   (B) 
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Mock (Con) or stably OGT (human ncOGT)-expressing INS-1 cells were prepared.  
Whole cell lysates were prepared from a subconfluent condition and blotted for ncOGT 
and mitochondrial OGT (mOGT) expression levels.  (C) Mock (Con) or ncOGT stable 
INS-1 cells were transiently transfected with Akt1 WT or S473A mutant.  Two days 
after transfection, lysates were prepared and used for standard Western blots for the 
indicated molecules (lysate) or immunoprecipitated (IP) with anti-O-GlcNAc antibody 
(RL2 clone) prior to Akt1 immunoblots (bottom panel).  Both mannitol and glucose 
were included into the treatment for osmotic compensation (not depicted), as in Fig. 1.  
The relative pS473Akt1 and O-GlcNAc-modified Akt1 levels under diverse experimental 
conditions were calculated for graphic presentation (mean ± standard deviation).  * 
indicates p values < 0.05 for significant differences.  Data shown represent at least 
three different assays. 
 
Fig. 7.  Akt1 WT, but not the S473A mutant, associates with OGT following 
glucosamine treatment.  INS-1 cells were transiently transfected with (HA)3-Akt1 
WT or S473A mutant.  One day later, the cells were treated with 7.5 mM glucosamine 
(GlcN) in the absence of serum for 14 h.  Both mannitol and glucose were included 
into the treatment for osmotic compensation (not depicted), as in Fig. 1.  After 
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incubation, cells were harvested for an immunoprecipitation with anti-HA antibody 
prior to OGT immunoblots.  Data shown represent at least three independent assays.
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Table 1.  Predicted O-GlcNAc sites of Akt1 protein sequence by YinOYang 2.11. 
 




Akt1 122 S ++ 0.5080 0.4017 0.4918
Akt1 430 T ++ 0.5647 0.4071 0.4992
Akt1 473 S ++ 0.6456 0.4484 0.5548
Akt1 479 T + 0.3882 0.3791 0.4614
 
 1) (http://www.cbs.dtu.dk/services/YinOYang/) 
   2) The higher potential value is, the higher the tendency to be modified with O-
GlcNAc is. 
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